Login to Your Account

Domantis Raises US$33M For Program In Domain Antibodies

By Karen Pihl-Carey

Tuesday, February 24, 2004
Domantis Ltd. raised US$33 million in a Series B financing that could take the company into clinical trials with its lead domain antibody (dAb) therapeutics. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription